title: [Does the public sector have an independent research role in the development of drugs?].
abstract: Exclusively private companies do drug development. The State contributes with education of academics and basic research constituting the basis of half of the drugs developed by the private companies. The Danish private drug research amounts to six billion DKK per year, corresponding to the estimated price of the development of one new drug. The development shows a negative tendency. There are doubts about the scientific credibility, the number of new drugs is declining, drug development costs are rising, and the competitiveness in Europe is declining compared with the one of The United States. Continued improvement of Danish drug development can be achieved by stimulation of the public research related to drug development.
authors.affiliation: Klinisk Farmakologisk Afdeling Q 7642, H:S Rigshospitalet, DK-2100 København ø. henrikep@rh.dk
authors.forename: Henrik Enghusen
authors.initials: HE
authors.lastname: Poulsen
authors.forename: Thor Buch
authors.initials: TB
authors.lastname: Grønlykke
mesh_terms: D003718:Denmark; D017277:Drug Approval / Q000191:economics; D016527:Drug Costs; D004345:Drug Industry / Q000191:economics / Q000458:organization & administration*; D015507:Drugs, Investigational / Q000191:economics; D005060:Europe; D006801:Humans; D017149:Private Sector / Q000191:economics; D017150:Public Sector / Q000191:economics; D012106:Research / Q000191:economics; D012109:Research Support as Topic / Q000191:economics; D014481:United States
chemical_list: D015507:Drugs, Investigational